Published on 26 Aug 2023 on Simply Wall St. via Yahoo Finance
CureVac N.V. (NASDAQ:CVAC) Analysts Just Trimmed Their Revenue Forecasts By 19%
Today is shaping up negative for CureVac N.V. (NASDAQ:CVAC) shareholders, with the analysts delivering a substantial negative revision to this year's forecasts. There was a fairly draconian cut to their revenue estimates, perhaps an implicit admission that previous forecasts were much too optimistic.
Following the downgrade, the most recent consensus for CureVac from its eight analysts is for revenues of €55m in 2023 which, if met, would be a substantial 46% increase on its sales over the past 12 months. Prior to the latest estimates, the analysts were forecasting revenues of €68m in 2023. It looks like forecasts have become a fair bit less optimistic on CureVac, given the substantial drop in revenue estimates.
Check out our latest analysis for CureVac